All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Wavelength-Pharmaceuticals-Insert

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Theratechnologies

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Theratechnologies Confirms Bioequivalence of New Tesamorelin Formulation

Contact the Supplier

Lead Product(s): Egrifta

Therapeutic Area: Infections and Infectious Diseases Product Name: F8

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 07, 2020

Details:

This new formulation, known as “F8”, is stable at room temperature for up to seven days after reconstitution and its volume of administration is only 0.16 mL making it possible to have a single multidose vial containing seven days of treatment.